AGIO
Price:
$48.64
Market Cap:
$2.77B
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.[Read more]
Industry
Biotechnology
IPO Date
2013-07-24
Stock Exchange
NASDAQ
Ticker
AGIO
According to Agios Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is 70.20%. This represents a change of 1.24% compared to the average of 5.23% of the last 4 quarters.
The mean historical ROE of Agios Pharmaceuticals, Inc. over the last ten years is -30.80%. The current 70.20% ROE has changed -327.92% with respect to the historical average. Over the past ten years (40 quarters), AGIO's ROE was at its highest in in the March 2021 quarter at 81.61%. The ROE was at its lowest in in the December 2020 quarter at -24.44%.
Average
-30.80%
Median
-46.87%
Minimum
-83.91%
Maximum
124.21%
Discovering the peaks and valleys of Agios Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 541.00%
Maximum Annual ROE = 124.21%
Minimum Annual Increase = -248.02%
Minimum Annual ROE = -83.91%
Year | ROE | Change |
---|---|---|
2023 | -43.41% | 541.00% |
2022 | -6.77% | -105.45% |
2021 | 124.21% | -248.02% |
2020 | -83.91% | 35.51% |
2019 | -61.92% | 23.03% |
2018 | -50.33% | -39.94% |
2017 | -83.80% | 51.41% |
2016 | -55.35% | 62.24% |
2015 | -34.11% | 170.57% |
2014 | -12.61% | -57.93% |
The current ROE of Agios Pharmaceuticals, Inc. (AGIO) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
24.67%
5-year avg
-14.36%
10-year avg
-30.80%
Agios Pharmaceuticals, Inc.’s ROE is greater than Mereo BioPharma Group plc (-69.11%), greater than Blueprint Medicines Corporation (-47.66%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), less than BioMarin Pharmaceutical Inc. (6.22%), greater than IDEAYA Biosciences, Inc. (-19.42%), greater than AnaptysBio, Inc. (-287.94%), greater than MeiraGTx Holdings plc (-80.95%), greater than Keros Therapeutics, Inc. (-41.74%), greater than Homology Medicines, Inc. (-100.91%), greater than Kymera Therapeutics, Inc. (-24.96%), greater than Revolution Medicines, Inc. (-33.67%), greater than C4 Therapeutics, Inc. (-42.45%), greater than Nurix Therapeutics, Inc. (-63.39%), greater than Relay Therapeutics, Inc. (-45.75%), greater than Stoke Therapeutics, Inc. (-54.45%), greater than Pliant Therapeutics, Inc. (-48.91%), greater than Black Diamond Therapeutics, Inc. (-68.08%), greater than Arvinas, Inc. (-50.26%), greater than Syndax Pharmaceuticals, Inc. (-64.34%), greater than Cogent Biosciences, Inc. (-70.85%), greater than Cullinan Oncology, Inc. (-26.54%), greater than KalVista Pharmaceuticals, Inc. (-103.92%), greater than Mersana Therapeutics, Inc. (-401.37%),
Company | ROE | Market cap |
---|---|---|
-69.11% | $587.99M | |
-47.66% | $6.01B | |
-22.40% | $1.36B | |
6.22% | $12.73B | |
-19.42% | $2.40B | |
-287.94% | $696.21M | |
-80.95% | $506.43M | |
-41.74% | $2.72B | |
-100.91% | $3.02M | |
-24.96% | $2.83B | |
-33.67% | $8.58B | |
-42.45% | $295.77M | |
-63.39% | $1.46B | |
-45.75% | $786.70M | |
-54.45% | $728.83M | |
-48.91% | $903.68M | |
-68.08% | $135.24M | |
-50.26% | $1.72B | |
-64.34% | $1.33B | |
-70.85% | $1.07B | |
-26.54% | $739.49M | |
-103.92% | $461.56M | |
-401.37% | $315.01M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Agios Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Agios Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Agios Pharmaceuticals, Inc.'s ROE?
How is the ROE calculated for Agios Pharmaceuticals, Inc. (AGIO)?
What is the highest ROE for Agios Pharmaceuticals, Inc. (AGIO)?
What is the 3-year average ROE for Agios Pharmaceuticals, Inc. (AGIO)?
What is the 5-year average ROE for Agios Pharmaceuticals, Inc. (AGIO)?
How does the current ROE for Agios Pharmaceuticals, Inc. (AGIO) compare to its historical average?